Main Conference Day 3 (30th April 2026) - CET/CEST (Cent Europe Summer, GMT+2)
Accurate prediction of final clone performance and stability with AI/ML models
Utilising AI/ML for:
Reduction in number of clones required for downstream
Improving identification of top-tier producers
Overcoming data infrastructure and validation challenges for successful implementation into a GMP workflow
- Adam Brown, Ph.D. - Professor of Biopharmaceutical Engineering, University of Sheffield
- Mario Gimona - Head of R&D 'Nanovesicular Therapeutics', Ludwig Boltzmann Institute of Nanovesicular Precision Medicine & Paracelsus Medical University, Austria
- Giovanni Ganendra - Upstream Process Science Senior Scientist, UCB Pharma
- Dong-Qiang Lin - Professor, Zhejiang University
- Maria del Carme Pons Royo - Postdoctoral Associate, Massachusetts Institute of Technology (MIT)
Mastering the critical process parameters of LNP manufacturing
Utilising tools such as microfluidic mixing systems to precisely control particle size and polydispersity.
Strategies to ensure consistent particle attributes and encapsulation efficiency from lab to GMP scale-up
- Lior Shaltiel - CEO, NurExone Biologic
Have a Solution for This Challenge?
This session is your platform to demonstrate leadership and technical expertise. Present your data, case studies, and innovative solutions to a targeted audience of senior scientists and engineers looking to solve hurdles in their production processes.
To learn more about sponsoring this session, contact us at Partners@informaconnectls.com
- Christian Witz - CEO, SimVantage GmbH
- Jane Worthington - Global Change Facilitator/Project Manager, BioPhorum
- Maria Boulieri - Lead Privacy Counsel, Chiesi Group
- David Pfister - Head of Research & Development, Ypso-Facto
- Cornelia Walther - Principal Scientist Downstream Development | Development Operations Vienna, Boehringer Ingelheim RCV GmbH & Co KG
- Paula Meleady - Associate Professor, School of Biotechnology, Dublin City University
- Zeynep Betts, PhD - Postdoctoral Research Associate, University of Manchester
Engineering the upstream process to control CQAs of the antibody backbone: improving conjugation efficiency and stability of subsequent ADCs
Implementing strategies to minimise aggregation and fragmentation.
Development of robust upstream processes to enable a more consistent/high-yield downstream conjugation process
- A Representative from Genmab - (Pending Final Confirmation), Genmab
- Tiffany Rau, PhD - Adjunct Professor Biochemistry and Cell Biology, University College Cork, Ireland
- Romain Nootens - Senior Process Engineer, UCB Pharma S.A.
- Manel Juan - Head of the Immunology Department, Hospital Clínic de Barcelona, Spain
- Manel Juan - Head of the Immunology Department, Hospital Clínic de Barcelona, Spain
- Tiffany Rau, PhD - Adjunct Professor Biochemistry and Cell Biology, University College Cork, Ireland
Have a Solution for This Challenge?
This session is your platform to demonstrate leadership and technical expertise. Present your data, case studies, and innovative solutions to a targeted audience of senior scientists and engineers looking to solve hurdles in their production processes.
To learn more about sponsoring this session, contact us at Partners@informaconnectls.com
- A Representative from Johnson & Johnson Innovative Medicine - (Pending Final Confirmation), Johnson & Johnson Innovative Medicine
- Christian Witz - CEO, SimVantage GmbH
Have a Solution for This Challenge?
This session is your platform to demonstrate leadership and technical expertise. Present your data, case studies, and innovative solutions to a targeted audience of senior scientists and engineers looking to solve hurdles in their production processes.
To learn more about sponsoring this session, contact us at Partners@informaconnectls.com
- Katharina Bruno-Thakur - Principal Scientist, F. Hoffmann-La Roche
Pinpointing the bottlenecks: do the biggest barriers to productivity come from cell biology, media formulation, bioreactor hardware, or process control?
Will AI and synthetic biology drive progress to design ‘super-producer’ cell lines in silico?
Is a diverse range of hosts needed for new modalities, or will a single, universal platform (e.g. advanced CHO cell) dominate?
Unlocking the next order-of-magnitude increase in productivity: what breakthroughs are needed?
- Patrick Harnedy - Senior Principal Engineer, Eli Lilly
- Katharina Bruno-Thakur - Principal Scientist, F. Hoffmann-La Roche
Pinpointing the bottlenecks: do the biggest barriers to productivity come from cell biology, media formulation, bioreactor hardware, or process control?
Will AI and synthetic biology drive progress to design ‘super-producer’ cell lines in silico?
Is a diverse range of hosts needed for new modalities, or will a single, universal platform (e.g. advanced CHO cell) dominate?
Unlocking the next order-of-magnitude increase in productivity: what breakthroughs are needed?
- Patrick Harnedy - Senior Principal Engineer, Eli Lilly
Approaching change on a large scale
Planning for phased implementation of sustainability practices
Seamless integration into existing workflows
Validation of new processes, technologies, etc.
Measurable impacts on carbon footprint
- Ana Cecilia Afonso Roque - Professor in Bioengineering, NOVA University of Lisbon
- Matthias Müllner - CEO, bespark*bio
- Mark Duerkop - Chief Executive Officer, Novasign, Austria
Identifying key cost drivers:
Raw Materials
QC
Labour
Etc.
How can targeted automation deliver efficiency?
Data-driven strategies to deliver significant cost reductions and open accessibility for patients worldwide
- Kat Kozyrytska - Founder, Cell Therapy Manufacturability Program
- Andrew Harmon - Associate Manager, Strategic Consulting, Sia Partners
- Matthias Müllner - CEO, bespark*bio
- Mark Duerkop - Chief Executive Officer, Novasign, Austria
Identifying key cost drivers:
Raw Materials
QC
Labour
Etc.
How can targeted automation deliver efficiency?
Data-driven strategies to deliver significant cost reductions and open accessibility for patients worldwide
- Kat Kozyrytska - Founder, Cell Therapy Manufacturability Program
- Andrew Harmon - Associate Manager, Strategic Consulting, Sia Partners